AtriCure (ATRC) Q1 2026 Earnings Transcript

Motley Fool Transcribing, The Motley Fool

Wed, May 6, 2026 astatine 9:30 AM CDT 36 min read

Image source: The Motley Fool.

DATE

May 5, 2026, 4:30 p.m. ET

CALL PARTICIPANTS

• President & Chief Executive Officer — Michael H. Carrel

• Chief Financial Officer — Angela L. Wirick

Full Conference Call Transcript

Michael H. Carrel: Great. Good afternoon, everyone, and invited to our call. AtriCure is disconnected to a beardown commencement successful 2026 with worldwide gross of $140 cardinal successful the archetypal quarter, reflecting 14% maturation year-over-year. We are gathering connected the momentum we established successful 2025 from caller merchandise launches with this 4th marking an acceleration successful our worldwide maturation complaint from the preceding 4th and comparable 4th past year. Fueling this acceleration is our U.S. business, which drove astir 15% successful the 4th from expanding adoption of AtriClip FLEX-Mini and PRO-Mini devices, cryoSPHERE MAX probe and continued spot from our EnCompass clamp. In addition, we generated $17 cardinal successful adjusted EBITDA, astir treble the archetypal 4th of past year.

Our results this 4th erstwhile again show our quality to present durable, double-digit gross maturation and grow profitability. Beyond our fiscal results, we person made exceptional advancement successful our BoxX-NoAF objective trial. Since initiating proceedings enrollment successful the 4th fourth of past year, we person enrolled astir 300 full patients. To day successful this 960-patient randomized controlled trial, we are tracking good up of our archetypal clip enactment and present expect to implicit enrollment astir the extremity of this year, astir 1 twelvemonth up of plan. The gait of enrollment successful this proceedings reflects an highly precocious level of engagement from surgeons who experienced firsthand the interaction postoperative Afib has connected their patients.

As a reminder, up to fractional of cardiac country patients without pre-existing Afib volition make postoperative Afib, which is the astir communal complication of cardiac surgery. Because determination is nary established attraction today, postoperative Afib is simply a important load connected the wellness attraction spending, with estimates exceeding $2 cardinal annually successful the U.S. alone. We are assured that our BoxX-NoAF objective proceedings utilizing our EnCompass clamp and AtriClip instrumentality has the imaginable to meaningfully alteration attraction outcomes for this diligent colonisation and code the important unmet objective need. BoxX-NoAF is besides highly complementary to our LeAAPS objective trial, studying changeable simplification payment of near atrial appendage absorption successful cardiac country patients without atrial fibrillation.

We expect some of our landmark objective trials to make robust objective grounds successful enactment of preventative attraction for cardiac country patients, unlocking a monolithic planetary marketplace accidental for AtriCure portion establishing caller standards of attraction successful cardiac surgery. We astatine AtriCure are good positioned to recognize these important catalysts for our concern successful the coming years. Now connected to updates covering franchise show successful the archetypal quarter. Pain absorption erstwhile again led our portfolio growth, expanding 28% year-over-year. The cryoSPHERE MAX probe continues to beryllium the superior operator of growth, contributing astir 70% of our symptom absorption income this quarter.